Sai Parenterals

What Sai Parenterals does

Sai Parenterals Limited, founded in 1989 and headquartered in Hyderabad, Telangana, is a diversified pharmaceutical formulations company operating two business verticals: Branded Generic Formulations and Contract Development & Manufacturing Organisation (CDMO) services. The company manufactures across multiple dosage forms—injectables (with sterile manufacturing for critical care and penicillin-based therapies delivered via dry powder injections, pre-filled syringes, ampoules, and vials), tablets, capsules, liquid orals, and ointments—and serves therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, VMS, analgesics, and dermatology. It operates six manufacturing facilities in Hyderabad, including two dedicated injectables facilities, a solid oral dosage facility, and a dedicated cephalosporin facility. The company serves central and state government agencies, pharmaceutical companies, institutions, and super stockists domestically, with exports to Australia, Southeast Asia, the Middle East, and Africa.

Sai Parenterals monetizes through one-time sales of branded generic formulations (domestic and export) and professional services revenue from CDMO engagements covering product development, regulatory dossier preparation, international filings, validation batches, and commercial manufacturing for pharmaceutical company clients. Its go-to-market is sales-led and enterprise-field-sales driven, relying on direct B2B engagement with government agencies and institutional buyers rather than consumer marketing. Pricing is not publicly disclosed.

In November 2025, the company acquired a 74.6% stake in Australian pharmaceutical company Noumed Pharmaceuticals Pty Ltd for Rs 125 crore ($13.9 million), gaining R&D, distribution, and a manufacturing facility in Adelaide expected to come online in late 2026. Noumed's full consolidation from Q4 FY26 onward contributed to FY26 revenue more than doubling to Rs 381 crore and net profit rising 45% to Rs 14 crore. Sai Parenterals went public via IPO in March 2026, raising Rs 408.79 crore (Rs 285 crore fresh issue plus Rs 123.79 crore offer for sale), with anchor investments from Morgan Stanley Asia (Singapore) and Kotak Mahindra Life Insurance. The company listed on NSE and BSE on April 2, 2026 under ticker SAIPARENT. IPO proceeds are earmarked for capacity expansion, R&D, and debt repayment.

Name

Sai Parenterals

Legal name

Sai Parenterals Limited

Website

https://saiparenterals.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

Sai Parenterals is a Hyderabad-based pharmaceutical formulations manufacturer founded in 1989, operating Branded Generic Formulations and CDMO verticals across injectables, orals, and cephalosporins for domestic government agencies, pharmaceutical companies, and international export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Pharmaceutical manufacturing
• Parenteral formulations
• Injectable manufacturing
• CDMO services
• Branded generics

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Branded Generic Formulations: Manufacture and sale of branded generic pharmaceutical formulations across therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, VMS, analgesics, and dermatology. Serves domestic customers including government agencies, pharmaceutical companies, institutions, and super stockists, as well as export markets.
2. CDMO Services: Contract Development and Manufacturing Organisation services providing end-to-end solutions covering product development, regulatory dossier preparation, international filings, validation batches, and commercial manufacturing for pharmaceutical companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Core offering

Sai Parenterals manufactures and sells pharmaceutical formulations across multiple dosage forms including injectables, tablets, capsules, liquid orals, and ointments through two business verticals: Branded Generic Formulations and Contract Development & Manufacturing Organisation (CDMO) services. The company operates six manufacturing facilities in Hyderabad, Telangana, producing formulations spanning therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, VMS, analgesics, and dermatology for domestic and international customers.

Product overview

Sai Parenterals is a diversified pharmaceutical formulations company operating two core business verticals: Branded Generic Formulations and CDMO (Contract Development and Manufacturing Organisation) services. The company manufactures products across multiple dosage forms including injectables (with sterile manufacturing for critical care and penicillin-based therapies, including dry powder injections, pre-filled syringes, ampoules, and vials), tablets, capsules, liquid orals, and ointments. Its portfolio spans therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins/minerals/supplements (VMS), analgesics, and dermatology. The company operates six manufacturing facilities in Hyderabad, Telangana, including two dedicated injectables facilities, a solid oral dosage facility, and a dedicated cephalosporin facility.

Differentiator

Problem solved

Functional benefit

Products and services

• Branded Generic Formulations Manufacture and sale of branded generic pharmaceutical formulations across multiple therapeutic areas and dosage forms, serving domestic central and state government agencies, pharmaceutical companies, institutions, and super stockists, with exports to regulated and semi-regulated international markets.
• CDMO Services End-to-end Contract Development and Manufacturing Organisation services covering product development, regulatory dossier preparation, international filings, validation batches, and commercial manufacturing for pharmaceutical company clients.

Quantifiable outcome

• Revenue more than doubled to Rs 381 crore in FY26 from revenue growth driven by full consolidation of subsidiaries following the Noumed acquisition.

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Noumed Pharmaceuticals Pty LtdcoreStrategic or Co-development Partner · 25 November 2025Sai Parenterals acquired a 74.6% equity stake in Australian pharmaceutical company Noumed Pharmaceuticals Pty Ltd for Rs 125 crore ($13.9 million) in November 2025, through a combination of secondary purchase from Noumed Life Sciences Limited and primary subscription via convertible loan. The acquisition aims to leverage Noumed's R&D, distribution, and upcoming manufacturing capabilities (facility in Adelaide expected operational in late 2026) to expand Sai Parenteral's presence in regulated markets and enhance its product offerings. Noumed became a subsidiary with full consolidation from Q4 FY26 onward, contributing to more than doubling of revenue.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Gland Pharma: Gland Pharma is a leading India-based injectable-focused pharmaceutical manufacturer with a CDMO business, making it the closest direct peer to Sai Parenterals' sterile injectables and CDMO verticals. Both companies operate in sterile manufacturing with pre-filled syringes, vials, and ampoules for global markets.
• Strides Pharma Science: Strides Pharma is an Indian pharmaceutical company with a strong focus on oral solid dosage forms and sterile injectables for regulated markets, including the US. Comparable to Sai Parenterals in generic formulation manufacturing and CDMO services across multiple therapeutic areas.
• Bharat Serums and Vaccines: Bharat Serums specializes in sterile injectable formulations including biologicals and critical care products, with strong domestic and emerging market presence. Highly comparable to Sai Parenterals' critical care and penicillin-based sterile injectables portfolio.
• Biological E: Biological E is an Indian injectable and biological products manufacturer with a CDMO business, operating sterile injectable facilities and serving global markets. Comparable to Sai Parenterals in sterile injectable manufacturing and CDMO contract services.

Broad incumbents

• Aurobindo Pharma: Aurobindo Pharma is one of India's largest generic pharmaceutical manufacturers with a substantial injectables portfolio and global CDMO presence. Overlaps broadly with Sai Parenterals in generic injectables, tablets, and capsules, but at materially larger scale.
• Piramal Pharma: Piramal Pharma operates a global CDMO business across sterile injectables and complex generics. Comparable to Sai Parenterals in CDMO services and sterile manufacturing capabilities, though with a much broader global footprint.
• Cadila Healthcare (Zydus): Zydus is a broad Indian pharmaceutical player with injectable, oral solid, and biosimilar capabilities, plus domestic institutional and government supply channels comparable to Sai Parenterals' branded generics vertical.
• Syngene International: Syngene is an Indian-based contract development and manufacturing organization serving global pharmaceutical companies. Comparable to Sai Parenterals in the CDMO vertical, although Syngene focuses more on discovery and biologics manufacturing services.

Emerging players

• Panacea Biotec: Panacea Biotec is an Indian pharmaceutical company with a branded generics and vaccines portfolio including sterile injectables. Smaller scale peer with overlap in domestic institutional supply and sterile injectable formulations.
• Lincoln Pharmaceuticals: Lincoln Pharmaceuticals is a Gujarat-based Indian pharmaceutical company with branded generics across multiple dosage forms and therapeutic areas, including injectables. Comparable in scale and in domestic branded generic distribution through super stockist networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sai Parenterals